BPC-157 vs. TB-500: Tissue Repair Mechanisms and Research Comparison

Reviewed and corrected August 23, 2026 · Artemis Labs

BPC-157 vs. TB-500 — BPC-157 is a 15-amino-acid peptide (GEPPPGKPADDAGLV) that copies part of a protein found in human gastric juice. TB-500 is a synthetic seven-amino-acid peptide, Ac-LKKTETQ, matching residues 17–23 of thymosin β4, a 43-amino-acid protein. Animal and cell studies of BPC-157 have reported growth-factor and nitric-oxide effects; a review reported the LKKTETQ region promoted angiogenesis, wound healing and cell migration in the models it surveyed (Sosne 2010, PMID 20179146). Neither compound has a completed human efficacy trial, and no published study has tested the two together.

Research highlights

Correction to an earlier version of this page. TB-500 is seven amino acids, not five: Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln (Ac-LKKTETQ), molecular weight 889.0 g/mol, CAS 885340-08-9, PubChem CID 62707662. Two published papers state the acetylation explicitly — PMID 23084823 and PMID 22962027.
Most “TB-500” research is not TB-500. It studies full-length thymosin β4, the 43-residue parent protein. A 2026 review lists them as two separate compounds — “Tβ4 (thymosin beta-4), and TB-500 (thymosin beta-4 fragment)” (PMID 41966639).
BPC-157’s animal literature is broader. Published preclinical models cover tendon, ligament, muscle, gut, blood vessel, brain and eye tissue. Reported growth-factor upregulation (VEGF, EGF, HGF) comes from burn, fistula and ocular models (DOI 10.2147/DDDT.S82030; DOI 10.1016/j.lfs.2016.02.029; DOI 10.3390/ph16071052).
The pairing rationale is mechanism complementarity, not a demonstrated additive effect. No published study has tested the BPC-157 + TB-500 combination. Any number describing “how much better” the pair performs has no source behind it.

What are BPC-157 and TB-500?

Anyone reading about peptide research on tissue repair meets these two names quickly, usually side by side. They are not variants of each other. They come from different parent molecules, they have been studied in different laboratories for different questions, and — this is the part most comparisons skip — they have very different amounts of published evidence behind them.

BPC-157 is a 15-amino-acid peptide. Its sequence, GEPPPGKPADDAGLV, is a partial sequence of a protein found in human gastric juice. It has a run of three prolines at positions 3–5, a structural feature associated with unusual resistance to enzyme breakdown; published work reports it staying intact in human gastric juice for more than 24 hours.

TB-500 is a synthetic seven-residue peptide with an acetyl group capping one end: Ac-LKKTETQ. Those seven residues are positions 17–23 of thymosin β4, a naturally occurring 43-amino-acid protein weighing about 4,963 Da — roughly five and a half times heavier than the fragment. The acetyl cap is a real structural difference of +42 Da, and it is the form sold commercially, so the uncapped peptide’s weight (847.0 g/mol) is not TB-500’s weight. Thymosin β4 and TB-500 are related. They are not the same molecule, and reading a thymosin β4 study as a TB-500 study is the single most common error in this subject.

Side-by-side: identity and evidence base

Aspect	BPC-157	TB-500
Origin	Partial sequence of a protein found in human gastric juice	Synthetic copy of residues 17–23 of thymosin β4, acetylated at one end
Sequence	GEPPPGKPADDAGLV	Ac-LKKTETQ
Molecular size	15 amino acids · 1,419.54 g/mol	7 amino acids · 889.0 g/mol
CAS / PubChem	137525-51-0 / CID 9941957	885340-08-9 / CID 62707662
Mechanism most often reported	Growth-factor (VEGF, EGF, HGF) and nitric-oxide signalling in animal models	Actin binding — LKKTETQ is described as the central actin-binding region of thymosin β4
Published models	Tendon, ligament, muscle, gut, blood vessel, brain and eye models, largely in rats and mice	For the fragment itself: aged mice, an Alzheimer’s mouse model, an alkali-burn eye model, and a detection study in horses
Human evidence	No published Phase II or Phase III efficacy trial for any use	No published human trial of the fragment at all; human trials exist only for the 43-residue parent protein

What has BPC-157 actually been studied for?

Every item below is a bounded report from a named model. None of it is a human result.

Growth-factor upregulation. Increases in VEGF (vascular endothelial growth factor, the main signal for new blood-vessel formation), EGF (epidermal growth factor) and HGF (hepatocyte growth factor) were reported in an alkali-burn model (Huang 2015), a rectovaginal-fistula model in rats (Baric 2016), and an ocular review (Sikiric 2023).
Nitric-oxide system involvement. A rat study linked BPC-157 to the nitric-oxide pathway using L-NAME and L-arginine co-treatment (Amam 2018). In 2026, a tissue-bath study reported concentration-dependent, endothelium-dependent, nitric-oxide-mediated relaxation of human internal mammary artery rings left over from bypass surgery (PMID 42123221). That is human tissue in a lab dish — not a clinical trial.
Cell outgrowth and migration in culture. Faster tendon-cell outgrowth, survival and migration were reported through FAK–paxillin signalling (Chang 2011), with increased growth-hormone-receptor expression in tendon fibroblasts — the cells that build connective tissue — in a later paper (Chang 2014).
Connective-tissue healing in animals. Improved ligament healing was reported in a rat knee-ligament transection model (Cerovecki 2010), the foundational orthopaedic study for this compound.
Cytoprotection and gut models. A synthesis paper describes vascular recruitment and gastrointestinal healing across cytoprotection models (Sikiric 2018).

A structural caveat travels with all of it: BPC-157 has no single defined receptor, no canonical binding assay separating a positive from a null response, and effect sizes vary substantially with model, dose, route and species.

What has TB-500 actually been studied for?

This is where the honest answer is short, and where most comparisons on the internet quietly substitute the parent protein’s research for the fragment’s.

The fragment’s own literature is four papers. A 2003 study reported that “the actin-binding domain of thymosin beta 4 duplicated in a seven-amino acid synthetic peptide, LKKTETQ, was able to promote repair in the aged animals comparable to that observed with the parent molecule” — aged mice, with no dose stated in the abstract (Philp 2003). A 2026 paper gave TB500 to cells and to transgenic Alzheimer’s-model mice and reported improved maze and object-recognition performance, while stating its own negative result plainly: hippocampal amyloid burden was unchanged (Ou 2026). A 2025 paper delivered the fragment in a hydrogel to an alkali-burned mouse and rabbit eye and called it “the first ocular application of TB500” (Lu 2025). The fourth is a doping-control detection assay in horses, not an efficacy study (Ho 2012).

The actin claim, stated at the strength the source supports. A review describes “LKKTETQ, the central actin-binding domain (aa 17-23) plus 1 additional amino acid (Q)” as promoting “angiogenesis, wound healing, and cell migration” (Sosne 2010). That supports calling LKKTETQ an actin-binding region. It does not support the stronger mechanism wording that circulates on vendor pages and that an earlier version of this page repeated. We could not trace that wording to any abstract in our reference set, so it has been removed rather than softened.

A class-level statement from an orthopaedic review. “Wound-healing peptides such as BPC-157, TB-500, and GHK-Cu promote angiogenesis, integrin-mediated extracellular matrix remodeling, and fibroblast activation” (Rahman 2026). The same abstract notes “a current lack of clinical trials.” It is a narrative review’s summary of a compound class, not an experiment on TB-500.

And one finding that complicates all of it. A 2024 pharmacology paper opens: “The biological effects of TB-500, however, have not been documented.” It tracked TB-500 breakdown in human serum, in enzyme systems, and in urine from treated rats, and concluded that “the previously reported wound-healing activity of TB-500 in literature may be due to its metabolite Ac-LKKTE rather than the parent form” (Rahaman 2024). Read plainly: it is not settled that the seven-residue molecule sold as TB-500 is the active species at all.

Has anyone studied the two together?

No. There is no published study of the BPC-157 + TB-500 combination — not in animals, not in cells, not in people. Neither of the two independent literature passes behind this page found one.

That matters for how the pairing gets described. The reason the two appear together is mechanism complementarity: BPC-157’s reported effects cluster around growth-factor and nitric-oxide signalling, while the region TB-500 copies is described as an actin-binding domain involved in cell migration. Those are different processes, so combining them is a coherent research idea. Coherent is not the same as demonstrated.

An earlier version of this page attached percentages to that idea — figures suggesting one compound delivered a given share of “maximum benefit” and the pair delivered more. Those numbers had no source and read as efficacy claims. They have been removed and no substitute figure exists, because no combination study exists to produce one. The same applies to the pre-formulated blends: GLOW (GHK-Cu 50 mg + BPC-157 10 mg + TB-500 10 mg) and KLOW (GLOW plus KPV 10 mg) are formulations, and no published study has tested any of them.

Where each compound has published work, by tissue

There is deliberately no “combined effect” column. A combined-effect column would require a combination study, and there isn’t one.

Research readout	BPC-157	TB-500 / thymosin β4
New blood-vessel formation	Reported in burn and ocular animal models (Huang 2015; Sikiric 2023); compared with standard angiogenic growth factors in a review (Seiwerth 2018)	Class-level review statement (Rahman 2026); LKKTETQ described as promoting angiogenesis (Sosne 2010)
Cell migration	Tendon-cell migration in culture via FAK–paxillin (Chang 2011)	Described for the LKKTETQ region in review (Sosne 2010)
Nitric-oxide signalling	Rat pharmacology (Amam 2018); human artery rings ex vivo (PMID 42123221)	No study located
Tendon, ligament, muscle	Rat ligament transection (Cerovecki 2010); mechanism review (Matek 2026)	No primary tendon, ligament or muscle study exists for either the fragment or the parent protein
Eye	Review of glaucoma and other animal ocular models (Sikiric 2023)	Parent protein reached human ophthalmic trials; an independent Cochrane review graded that evidence low-certainty (PMID 41347649). Fragment: one alkali-burn model (Lu 2025)
Heart	Animal cytoprotection and arrhythmia-model reviews (PMID 41901308)	Parent protein in a randomized 96-patient heart-attack trial: the overall comparison was not significant; only an early-dosing subgroup was (Zhang 2025)

What the research does not show

No human trial of TB-500 exists. Searches on TB-500, TB500 and LKKTETQ crossed with human, patient, adverse and safety terms return no human trial of the fragment. Every human study in this area used full-length thymosin β4.
No human musculoskeletal evidence for either form of thymosin β4. A 2026 review states that TB-4 and TB-500 “promoted angiogenesis and tissue repair in preclinical models, but human orthopaedic data are lacking” (Mayfield 2026). A PRISMA scoping review found 67% of publications used preclinical animal models and concluded that claimed benefits “remain unsubstantiated by current human trials” (Tewari 2026).
BPC-157 has no published Phase II or Phase III efficacy trial for any use. Its FDA compounding status is unsettled and should not be described as resolved.
Counter-evidence on thymosin β4. In an irritable-bowel-syndrome model, thymosin β4 released by mast cells reduced tight-junction proteins and impaired intestinal barrier integrity in rats and mice, with elevated thymosin β4 measured in the colonic mucus of IBS patients (Sun 2025). That study examined endogenous, full-length thymosin β4 — not the TB-500 fragment, and with no human dosing arm of any kind. We surface it because honest disclosure is the standard we hold ourselves to, not because it transfers directly.
Product-content risk is documented. A drug-testing paper on TB500/TB1000 products concluded: “We confirm that the content of TB500/TB1000 products is not systematically consistent with it’s former descriptions” (Delcourt 2023). Third-party identity and purity testing is the only defence against that.
Both are prohibited in sport. The WADA 2026 Prohibited List names, under S2.3, “Thymosin-β4 and its derivatives e.g. TB-500”; S2 substances are prohibited at all times (WADA Prohibited List). BPC-157 falls under the same section.

Common questions

Which one is “better”?

No published study has compared them head to head, so there is no result to report. What differs is the size of the evidence base: BPC-157 has primary animal studies across several tissue types, while TB-500 itself has four papers, none of them in humans. Most literature that appears to be about TB-500 is about the 43-residue parent protein.

Is TB-500 the same as thymosin β4?

No. TB-500 is a synthetic, acetylated seven-residue peptide matching residues 17–23 of thymosin β4. Thymosin β4 is a 43-residue protein about five and a half times heavier. A separate fragment, Ac-SDKP, comes from the other end of the same protein and is a third distinct molecule — some papers that look like thymosin β4 research are actually about that one.

Why are they described as a pair at all?

Because their reported mechanisms address different steps — signalling on one side, actin-dependent cell movement on the other. That is a rationale for studying them together. It is not evidence that they work better together, and no study has tested that.

What about KPV and GHK-Cu in the same blend?

Those blends exist as products, and the same rule applies: no published study has tested any of the combinations. On the components themselves — KPV is the C-terminal tripeptide of α-MSH, but its anti-inflammatory action operates largely independently of melanocortin receptors, entering cells and inhibiting NF-κB nuclear translocation (PMID 18061177; PMID 12750433), and its evidence is entirely preclinical. GHK-Cu has no controlled human trials of systemic use; its human evidence is topical-cosmetic, and the most-cited trial tested a multi-ingredient formulation, so effects cannot be attributed to the peptide alone (PMID 19438432).

How do you verify research-grade material?

Ask for a lot-specific certificate of analysis showing reverse-phase HPLC purity, mass-spectrometry identity confirmation, and endotoxin testing. The identity check is concrete: BPC-157 should match GEPPPGKPADDAGLV and 1,419.54 g/mol; TB-500 should match Ac-LKKTETQ and 889.0 g/mol — and 847.0 g/mol would indicate the uncapped peptide, a different compound. Multi-component blends need a per-component chromatogram; per-component purity cannot be inferred from a single blend assay. Our HPLC testing explainer walks through reading one.

BPC-157 + TB-500 — 10 mg of each, supplied as two separate vials with lot-specific COA
KPV — the C-terminal tripeptide of α-MSH
GHK-Cu — copper-binding tripeptide

References

Philp D, et al. Thymosin β4 and a synthetic peptide containing its actin-binding domain promote dermal wound repair in aged mice. PMID 12581423
Sosne G, et al. Thymosin beta 4: a potential novel therapeutic agent for ocular disorders (review). PMID 20179146
Ho ENM, et al. Detection of TB-500 (N-acetylated LKKTETQ) in equine plasma and urine. PMID 23084823
Identification of the N-terminal acetylated 17-23 fragment of human thymosin beta 4 (Ac-LKKTETQ). PMID 22962027
Rahaman A, et al. Metabolism of TB-500 in human serum, enzyme systems and rat urine. PMID 38382158
Ou Z, et al. Thymosin β4-derived peptides TB500 and Ac-SDKP in Alzheimer’s disease models. PMID 41443105 · DOI 10.1016/j.intimp.2025.116097
Lu Y, et al. Enzyme-triggered hydrogel delivery of TB500 in an alkali-burn ocular model. PMID 41359360
Mendias CL, et al. Peptide therapies in musculoskeletal medicine. Sports Med. PMID 41966639
Mayfield CK, et al. Am J Sports Med, 2026. PMID 41476424
Rahman S, et al. Therapeutic peptides in orthopaedics. JAAOS Glob Res Rev. PMID 41490200
Tewari S, et al. Emerging peptide supplements for musculoskeletal recovery: PRISMA scoping review. PMID 42578445
Kruoch Z, et al. Interventions for neurotrophic keratopathy (Cochrane review CD015723). PMID 41347649
Zhang Y, et al. Recombinant human thymosin β4 in STEMI: randomized, placebo-controlled trial. Cardiovasc Res. PMID 41229390
Sun YS, et al. Thymosin β4 released by mast cells impairs the intestinal epithelial barrier via IL22RA1/JAK1/STAT3 in IBS. World J Gastroenterol. PMID 41278163 · DOI 10.3748/wjg.v31.i42.111706
Delcourt V, et al. TB500/TB1000 and SGF1000: misbranded and adulterated drugs. Drug Test Anal. PMID 36482504
Huang T, et al. BPC-157 in alkali-burn wound healing. DOI 10.2147/DDDT.S82030
Baric M, et al. BPC-157 in rectovaginal fistula repair in rats. DOI 10.1016/j.lfs.2016.02.029
Sikiric P, et al. BPC-157 in ocular animal models (review). DOI 10.3390/ph16071052
Amam I, et al. BPC-157 and the nitric-oxide system in a rat venous-occlusion model. DOI 10.3748/wjg.v24.i47.5366
Yildirim S, et al. BPC-157 and endothelium-dependent relaxation of human internal mammary artery ex vivo. PMID 42123221
Chang CH, et al. BPC-157 and tendon fibroblast outgrowth via FAK–paxillin. DOI 10.1152/japplphysiol.00945.2010
Chang CH, et al. BPC-157 and growth-hormone-receptor expression in tendon fibroblasts. DOI 10.3390/molecules191119066
Cerovecki T, et al. BPC-157 in a rat medial collateral ligament transection model. DOI 10.1002/jor.21107
Sikiric P, et al. BPC-157 cytoprotection and gastrointestinal healing (review). DOI 10.2174/1381612824666180608101119
Seiwerth S, et al. BPC-157 compared with standard angiogenic growth factors. DOI 10.2174/1381612824666180712110447
Matek D, et al. BPC-157 in tendon, ligament and muscle mechanisms (review). PMID 41754849
Sikiric P, et al. BPC-157 cytoprotection in hemorrhage and thrombosis models. PMID 41901308
KPV and NF-κB nuclear translocation. PMID 18061177; KPV action independent of melanocortin receptors in crystal-induced peritonitis. PMID 12750433
Multi-ingredient cosmetic formulation containing GHK-Cu, randomized trial. PMID 19438432
World Anti-Doping Agency, 2026 Prohibited List, section S2.3. wada-ama.org/en/prohibited-list

Methodology: this page draws only on the verified Artemis facts sheets for BPC-157 and thymosin β4 / TB-500, each built by re-reading the cited abstracts directly through NCBI E-utilities and confirming compound identity against PubChem. Corrections applied and links re-verified August 23, 2026. Claims that could not be traced to a cited abstract were removed rather than rewritten.

All compounds sold by Artemis Labs are for laboratory research use only. Nothing on this page is medical advice, and no statement has been evaluated by the FDA.

BPC-157 vs TB-500: Tissue Repair Comparison 2026 | Artemis Labs